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A STUDY ON PROGNOSTIC SIGNIFICANCE OF QTc INTERVAL IN 
THE INITIAL ECG OF OPC POISONING PATIENTS. 
BACK GROUND: 
Thanjavur being the rice bowl of Tamilnadu which is surrounded by numerous 
villages the use of pesticides particularly OPC are higher here. So it is a ideal place 
to study the clinical profile and prognostic factors in OPC poisoning. 
 In OPC poison apart from respiratory failure, cardiotoxicity also plays a major 
part in determining the mortality .Though the exact pathophysiology has not been 
studied, we are analyzing one such manifestation of cardiotoxicity as a predictor of 
mortality.  
AIMS AND OBECTIVES: 
To calculate the QTc interval in the initial ECG before atropinization and to  
correlate with outcome of the patient. 
MATERIALS AND METHODOLOGY: 
70 Patients admitted in thanjavur medical college with history of OPC poisoning 
with container were taken for our study. Relevant Clinical examination done and 
recorded. A 12 lead ECG taken before treatment. QTc interval calculated using 
Bazzets formula.Results analysed statistically. 
RESULTS: 
Most of the patients in our study group are males with suicide being the common 
cause. In our place monochrotophos and chlorpyriphos are the common 
compounds encountered. 
We classified our group in to those having normal, intermediate and prolonged 
QTc. 62% had prolonged QTc interval.  
Among the total 12 death 9 (75%) belong to the group with prolonged QTc. There 
is a statistically significant difference in mortality. So QTc interval definitely has a 
significant prognostic value in OPC poisoning. 
CONCLUSION: 
So early detection of QTc prolongation in ECG and initiation of early intensive 
treatment for OPC poisoning may reduce the mortality. 
Key words :  OPC- organophosphorus poisoning ; QTc - corrected QT interval 
INTRODUCTION 
India being one of the most developing country with numerous scientific 
technologies but still having agriculture as its backbone. So even with lot of 
developments in various fields of agriculture the use of pesticide is a must in all 
stages of agriculture. 
But  the sad part of it is in our country the pesticide use meant not only to kill 
pests but also  taking out many of human life 2, in the form of suicidal 
,accidental or homicidal poisoning. Incidence of poisoning by pesticides has  
been increasing in recent decades. Insecticides  are  the  most  commonly  used  
pesticides  in  the  developing  countries1. 
WHO estimates that there are about 3 million pesticide poisoning cases reported 
annually with relatively increased cases reported in developing countries like 
India. 
Among pesticides,  Organophosphorus  is  the  most  common  cause of acute 
poisoning. Among the different mode of poisoning, suicidal poisoning is the 
commonest in developing countries.   
Even though definitive antidote is available for OPC poisoning the mortality 
rate is quite high when compared to other pesticide for which there is no 
specific antidote. There are various prospective trials in comparing the different 
prognostic factors between death and survival groups of organophosphorus 
poisoning. 
 
Most of the important factors like  the duration of ventilator use, dose and 
duration  of atropine needed ,level of urine organophosphate3 and duration it 
was being excreted were similar in both groups. 
Almost all these parameters indirectly reflect the enhanced muscarinic and 
nicotinic activities , apart from this cardiotoxicity is also a part of OPC toxicity4. 
One such parameter reflecting this is QTc interval in OPC poisoning before 
atropinisation. 
In the absence of traditionally used prognostic marker like serum cholinesterase 
which is little bit costlier, Electrocardiogram which is available in every health 
care level can be used as a comparable prognostic indicator. 
Here in Thanjavur which is called to be Rice bowl of Tamil Nadu is surrounded 
by villages & villagers ,where plenty of person will be handling with this 
pesticide ,it is a ideal place for conducting  a study in OPC poisoning. So my 
topic will be a study comparing the outcome of OPC poisoning with the help of 
initial  ECG taken before atropinisation.  
 
  
AIMS & OBJECTIVES 
 
1 . To correlate  their   QTc interval in the initial ECG with the outcome.    
 
2 .  To evaluate the clinical profile of patients admitted for OPC poisoning. 
 
 
So the main aim is to found out whether QTc prolongation can be used as a 
prognostic indicator for OPC poisoning based on their clinical presentation. 
 
 
 
 
 
 
 
 
 
HISTORICAL REVIEW. 
It was  M.J.B.Orfila who Modern toxicology started in 1789 – 1853 A.D . 
He was a physician from Island of Minorca . He wrote the first book which 
totally describes the injurious effects of chemicals . He defined the toxicology 
and distinguished into chemical toxicology , forensic toxicology and analytical 
chemistry5.  
In 1831 , Mein separated and described atropine. In 1854 Clermont described 
TEPP 6 .TEPP is tetra ethyl pyrophosphate which is highly active. In 1867 
,Bezold and Bleobaum described the activity of atropine that blocks the cardiac 
manifestations of vagal stimuli . In 1914 , Dall assumed the enzyme esterase . It 
was later described by Nauratal and Plattner . In 1930 , Stedman gave the name 
as cholinesterase7 . In 1932 Lange and Krueger synthesized dimethyl and 
diethyl phosphoro fluoridate . In 1946 , McCombie and Saunders described 
DFP 8. DFP is diisopropyl fluoro phosphate .It was enumerated by scientists . In 
1952 , Schrader described the structure required for insecticidal activity . In 
1955 , Wilson and Ginsberg described 2- pyridine aldoxime9 . It has the ability 
to reactivate cholinesterase enzyme when it is inhibited by organophosphorus 
compound.  
In India , organophosphorus poisoning was initially explained by Viswanathan 
Et al in 1962.10 
 INCIDENCE OF ORGANOPHOSPHORUS POISONING 
 
In 1974 , the World Health Organization estimated that around 5 lakhs cases of 
pesticidal poisoning occurred yearly worldwide 11. Among this 9000 and above 
were died . In this deaths 99 % occurred in developing countries.12  In 1981 , 
there was 750 ,000 cases . In 1983 , the number raised to 2,000,000 . Of these 
40,000 deaths reported .In 1990 ,there was around 3,000,000 cases ,among 
which 2,000,000 fatalities reported. 
Incidence in India : 
• P.G.Kamath from G.T. Hospital Mumbai ,gave report that among 
poisoning cases , 34% were organophosphorus poisoning.13 
• During 1984 – 1988 ,  J Sunder Ram gave a report . He reported 69 % 
occurrence of organophosphorus poisoning among total poisoning 
cases.14 
• Singh et al gave a report of 19.23% incidence . He reported it from 
G.B.Pant Hospital , New Delhi.15 
 
 
 
 CHEMISTRY16 
OP COMPOUND 
Organophosphorus has central phosphorus atom bind to oxygen atom, two alkyl 
group and one leaving group . The liquid form of organophosphorus are 
volatile, so poisoning through inhalation also occur . Other route are ingestion, 
dermal absorption.  
                                     
 
Irrespective of route of entry, it diffuse into blood stream , transport to various 
organ system, here it move towards the nerve synapse and binds to 
acetylcholine esterase. After some time it depends upon the compound type 
organophosphorus-esterase bonds will mature through dealkylation of 
organophosphorus. Through maturation the bond become irreversible leading to 
destruction of both organophosphorus and acetylcholine esterase . 
Organophosphorus compounds are categorized into two groups: 
                   
      1. Alkyl phosphates – they are direct inhibitors. 
• Example. Malathion. 
• They manifest as acute cholinergic crisis. 
• They do not manifest as delayed type of 
weakness. 
• The response to atropine is very quick. 
.2. Arylphosphates – they are indirect inhibitors. 
• Example. Parathion. 
• They do not manifest as acute cholinergic crisis. 
• But they develop severe persistent 
fasciculations. 
• They  manifest as delayed type of weakness. 
• The response to atropine is not rapid and the                
requirement is high. 
 
PHYSICAL & CHEMICAL PROPERTIES OF INDIVIDUAL  COMPOUNDS  
 
MONOCROTOPHOS:17,18 
 One of the highly hazardous organophosphorus  compound available in india is 
monocrotophos.it is an easily affordable and widely used in India. 
Monocrotophos poisoning occur most frequently as suicidal as well as 
accidental poisoning. 
Apart from being a  insecticide it is also an acaricide. Vinyl phosphate group in 
its structure  make it more toxic. In agricultural fields it is very  useful to 
controls  pests  on cotton, rice and sugarcane. It  is highly toxic irrespective of 
the modes of exposure like ingestion ,inhalation and skin exposure. 
Oral intake of 1200mg of monocrotophos is fatal to human being(according to 
Hayes and Laws 1993).WHO classified this compound as Class 1b i.e highly 
hazardous. 
CHOLORPYRIFOS19 
It is  o-o-diethyl o-(3,5,6-trichloro-2 pyrinidyl)-phosphorothioate.  It is one of 
the broad spectrum cholirinated organophospate insecticide and accaricide. it is 
also a nematocide.it  appears as white colored solid crystals with a mercaptan 
smell i.e smells like sulfur compounds present rotten eggs, onion, garlic and 
skunk.It has solubility of 1.4mg/dl at 25 degree C.  
Cholorpyrifos cause inhibition of both enzymes Neuropathy target esterase and 
Cholinesterase .Compared to other compounds the inhibition of NTE is more so 
chances of intermediate syndrome and delayed neuropathy are common.  
PHORATE20: 
It is o,o-Diethyl s-ethylthiomethyl phosphorodithioate .It is a non-biocumulative 
broad spectrum organophosphorous acaricide,insecticide. It is clear ,pale yellow 
mobile liquid with freezing point of -42.9. At room temperature phorate is 
stable for 2 years in media between of pH of 5-7.   
As with almost all compounds it is toxic by all routes of exposure. It is highly 
toxic to mammals and other non target organism. Phorate has no residual action. 
Most commonly used as granular formulation. 
PARATHION: Pure parathion is pale yellow in color, has smell of garlic 
,insoluble in water. 
AZAMETHIOPHOS: It is a phosphorothiotic acid. Azamethiophos is orange 
yellow granules or gray to white crystalline powder. It is primarily used for fly 
control. 
DIAZINON: Diazinon is an o-odiethyl o-ester. It is an insecticide ,used to kill 
the cockroaches, ants and fleas. It has low persistence in soil, half life of 2-4 
weeks. 
Toxic profile is comparatively less.  
MALATHION: Malathion is introduced in 1950.It is Diethyl thiobutanedioate.  
It is clear,brown to colourless liquid with garlic odour. It is a broad spectrum 
insecticide . It is used for control of sucking and chewing insecticide. Has half 
life of 1-25 days. In air it is rapidly degraded and has half life of one and days. 
 
ANATOMY OF THE AUTONOMIC NERVOUS SYSTEM: 
Two major division21 are 
1. Sympathetic (Thoraco lumbar) 
 2.   Parasympathetic (Craniosacral) 
Both division originate in nuclei within the CNS and exit from brain stem or 
spinal cord that give preganglionic  efferent fibers and terminate in motor 
ganglia. Preganglionic sympathetic fibers exit through thoracic and lumbar 
spinal nerve. Parasympathetic  preganglionic  fibers through third, seventh,  
ninth tenth cranial nerve & second ,third and fourth sacral spinal nerve roots. 
 Preganglionic sympathetic fiber are short and terminate in ganglia located at 
paravertebral chain22.  
Sympathetic preganglionic  fibers end in prevertebral  ganglia. From ganglion 
Postganlionic fibers  arise and innervate the target organ. Some  of 
preganglionic parasympathetic fibers end in ganglion located outside the organ. 
eg:  Ciliary, Submandibular  and Pterygopalatine ganglion, several pelvic 
ganglia. But most of Preganglionic  parasympathetic fibers end in ganglion on 
the organ. 
 
ENTERIC NERVOUS SYSTEM(ENS) : 
It is highly organized and large collection of neuron in the of the gastrointestinal 
tract. It is also called as third division of ANS. It is extend from esophagus to 
distal colon, control both motor and sensory activity of the gut. It includes 
myentric plexus of Auerbach and Submucous plexus of Meissner. It control 
motility and secretory cells in the mucosa . ENS function as semiautonomous 
manner .It utilize motor outflow of ANS for modulation of gastrointestinal 
motility and sensory information back to CNS. 
CHOLINOCEPTORS22:  
Acetylcholine has two receptor-muscarinic  receptor, nicotinic receptor. 
Muscarinic receptor is G protein coupled receptor, nicotinic receptor is a ligand 
gated channel. 
MUSCARINIC RECEPTOR: 
 These are selectively stimulated by muscarine  and blocked by Atropine. It 
present primarly on heart, blood  vessels, eye, smooth muscle, glands of 
gastrointestinal, respiratory and urinary tract, sweat glands and CNS .Also 
present in autonomic ganglia which play a modulator role. 
Muscarinic   autoreceptors are present prejunctionally   on  postganglionic 
cholinergic nerve endings its activation inhibit Ach release. 
 All blood vessels have muscarinic receptors  on the endothelium but lack 
cholinergic innervations .On endothelial cells activation which release EDRF 
which diffuses to the smooth muscle and cause relaxation. 
 
 
SUBTYPES OF MUSCARINIC RECEPTORS22:  
It has 5 subtypes M1,M2, M3, M4,M5. 
M1,M2,M3 are major subtypes. M4 and M5 are present mainly on nerve ending 
in brain and modulate the release of neurotransmitters. 
MECHANISM OF ACTION IN RECEPTOR LEVEL: 
 
M1 receptor: 
 It is a G protein coupled receptor located on autonomic ganglia, gastric glands, 
CNS cause depolarization, histamine release, and learning memory and motor 
function respectively. 
It act through IP3/DAG second messenger leads to increased cytosolic calcium, 
activation of phospholipase A2 cause increased prostaglandin  synthesis.   
Agonist of M1 receptor:  Oxotremorine,MCN-343A  
Antagonist of M1 receptor: Pirenzepine and Telenzepine 
M2 RECEPTOR: 
 It is also G protein coupled receptor. Act by potassium channel opening, 
decreases the cyclic AMP.  
Present on SA node , activation  of which cause hyperpolarization ,decreased 
rate of impulse generation; AV node- decrease the velocity of conduction; 
Atrium- shortening of APD duration, decrease the contractility; in ventricle- 
also it  decrease the contractility . 
 CNS cause tremor, analgesia, visceral smooth muscle contraction . 
Agonist : Methacholine  
Antagonist:  Methoctramine, Tripitramine . 
M3 RECEPTOR: Acts via G protein coupled receptor mechanism same as M1 
receptor. It is present in visceral smooth muscle, ciliary muscle, iris, exocrine 
glands and vascular endothelium release NO cause vasodilatation . 
Bethanechol is a agonist 
Darifenacin is a antagonist. 
NICOTINIC RECEPTOR: 
 Nicotinic receptors  are selectively activated by nicotine. 
Antagonized by Tubocurarine and Hexamethonium.  
Activation cause opening of the channel and rapid flow of cations , 
depolarization ,an action potential.  
NM receptor: 
 Present in skeletal muscle endplate , mediate skeletal muscle contraction.  
Phenyltrimethyl ammonium is a agonist, tubocurarine is a antagonist. 
NN receptor:  
Present on ganglionic cells, adrenal medulary cells, and spinal cord ,some areas 
of brain. 
Dimethyl phenyl piperazinium is a agonist. Hexamethonium is a antagonist. 
ADRENOCEPTOR:  
It is classified in to Alpha and beta receptor.  
These are membrane bound G-protein coupled receptors which act by 
modulating intracellular levels of second messenger cAMP or IP3/DAG. 
ALPHA RECEPTOR:  It is divided in to 2 types 
ALPHA 1 RECEPTOR:  
Present  post junctionaly on genitourinary smooth muscle cause contraction; 
glands-secretion; gut-relaxation; liver-glycogenolysis; heart-arrythmia. 
Phenylephrine, Methoxamine are selective agonist.  
Prazosin is selective antagonist. 
ALPHA2 RECEPTOR: 
It is present prejunctionally in nerve ending and postjunctionally in brain  
pancreatic beta cells, extrajunctionally in platelets and in certain blood vessels 
.stimulation of this receptor cause inhibition of transmitter release, decreased 
central sympathetic outflow,  vasoconstriction, decreased insulin release and 
platelet aggregation . 
Clonidine is selective agonist, Yohimbine is selective antagonist. 
BETA  ADERNOCEPTORS: 
It is divided in to Beta1, Beta2, Beta3 receptors. 
BETA 1 RECEPTOR:  
Present in JG cells in kidney and in heart.  
Dobutamine is selective agonist. Metiprolol and Atenolol are antagonist.   
BETA 2 RECEPTOR:  
Present in bronchi ,blood vessels, uterus, liver ,G.I. tract, urinary tract and eye. 
Salbutamol is a selective agonist.  
Propranolol is a Selective antagonist. 
BETA 3 RECEPTOR:  
Present in adipose tissue. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CLINICAL FEATURES 
The clinical features of OPC poisoning as described is mainly due to excess of 
acetylcholine which acts on both of  its receptor and produce a syndrome that  
mimic like parasympathetic over activity syndrome. 
Sequential triphasic illness that has been described in OPC poisoning includes  
 Acute cholinergic phase 
 Intermediate syndrome 
 OPIDN (OP induced delayed polyneuropathy)  
 CHOLINERGIC PHASE: 
The clinical features can be classified simply as   
1. Muscarinic features  
2. Nicotinic features (Wadia type-2 syndrome) 23 
3. Central nervous system (CNS) features 23 
MUSCARINIC MANIFESTATIONS: 
Otherwise called as (Wadia type-1 syndrome) 
Characterized by  
o Cardiovascular – decreased  pulse rate & BP 
o Respiratory25 - Rhinorrhea, bronchorrhea, bronchospas, non cardiogenic 
pulmonary edema. 
o Gastrointestinal– excessive salivation, nausea and vomiting, abdominal 
pain loose stools ,pancreatitis 26,27  ,sometimes fecal incontinence. 
o Ocular - Blurred vision, miosis , increased lacrimation. 
o Sweat glands: diaphoresis. 
The above said effects are usually acute and manifest within 24-48 hours 
of poison consumption. Most endangering period since mortalities are 
more common during this period. 
Bronchorrhea25 is the usual mechanism of early mortality in OPP. The origin of 
this excess amount of fluid is from the secretions from the glands in the airway 
as such and not exudation of fluid across the alveolar-capillary membrane.  
These secretion causes obstruction of upper and lower airways and the 
deposition  of these bronchial secretions into the alveolar sacs produces hypoxia 
which  is of  primary concern in the initial stages of the poisoning. 
NICOTINIC MANIFESTATIONS: 
o Weakness of muscles 
o Hyper/hypo reflexia 
o Fasciculations 
o Paralysis  
It is due to  persistent stimulation the synchrony is lost, leading to asynchronous 
excitation, which first leads to fibrillation of muscle fibres then later leading to 
paresis/complete paralysis. 
        
Though most of the time the patients presents with bradycardia in OPC 
poisoning, up to 20% patients present  with tachycardia in the initial stage itself 
even without atropine. It is due to the nicotinic effect of the acetylcholine.  
It is not known whether which manifestation will be predominate at time of 
presentation. So with respect to pulse rate we cannot predict the atropine 
response in whom nicotinic  manifestation predominate. 
1. Immunity : 
Parathion causes suppression of both IgM and IgG immunoglobulins. 
It suppresses the function of natural killer cell and cytotoxic T cells. 
ENDOCRINE AND METABOLIC ALTERATIONS:29,28 
Rise in plasma corticosterone level. 
Rise in TSH level. 
Non ketotic hyperglycemia. 
Glycosuria. 
Increased amylase levels 
TERATOGENIC EFFECTS30 : 
Prenatal deaths. 
Post natal deaths. 
Congenital abnormalities – vertebral anomalies ,limb abnormalities, cleft 
palate  polydactyly , hydroureter. 
REGULATION OF TEMPERATURE : 
Hypothermia. 
Increased diaphoresis. 
 CLINICAL SEVERITY GRADING 
1. WHO CLASSIFICATION FOR SEVERITY OF OPC POISONING30: 
MILD MODERATE SEVERE 
Anorexia 
Headache 
 Dizziness 
Miosis 
Tremors of the tongue 
and the eyelids 
Salivation ,  Sweating 
Lacrimation 
Urination  
Abdominal Cramps  
Muscular Tremor 
Bradycardia. 
 
Pin point pupils and 
non reactive pupils 
Diarrhoea 
Difficulty in breathing, 
Cyanosis 
loss of sphincter 
control convulsions 
 heart block, coma 
 
2. PARADENIYA  GRADING OF ORGANOPHOSPORUS  POISONING SCALE31: 
It was proposed by Senanayake N (1993) for grading the severity of 
organophosporus poisoning. It is based on clinical manifestaion of 
orgnophosporus poisoning. 
1.Miosis: 
0 point for pupil size of more than 2mm. 
One  point for pupil size of less than 2mm. 
Two points for pin point pupil . 
2.Muscle fasciculation: 
0 point for no fasciculation. 
One point for presence of fasciculation but not generalized or continuous. 
Two points for  generalized and continuous fasciculation with central cyanosis. 
3.Respiratory rate: 
0 point for respiratory rate of less than 20/min. 
One  point for respiratory rate of more than 20/min. 
Two  point for respiratory rate of more than 20/min with central cyanosis. 
4.Pulse rate: 
0 point for pulse rate of more than 60/min. 
One point for pulse rate of 41-60/min. 
Two points for pulse rate of less than 40/min. 
5.Level of consciousness: 
0 point for conscious and rational. 
One point for impaired and responds to verbal commands. 
Two points for impaired and no response to verbal commands. 
 Add one point if convulsion present. 
Total Score of 11 
Score of less than 4               -mild 
Score of 4-7                             -moderate. 
Score of more than 7              -severe. 
 
3.   BARDIN et al.,32 
Proposed revised grading for OP poisoning to assess the severity. 
Mild poisoning: 
1.History of opc intake or exposure. 
2.Mild signs : Normal consciousness 
                         Secretion 1+ 
                          Fasciculations 1+ 
Severe poisoning:  
Severe signs:  Altered consciousness   Secretions 3, Fasciculations 3+ 
Life threatening poisoning: 
Suicide attempt  ; Stupor.  
Pao2 less than 75 mmHg ; Abnormal chest roentgentogram. 
(1+ is mild secretion and few fasciculation, 3+is copious secretions and 
generalized faciculations.) 
4.  
5. DREISBACHs CLASSIFICATION33: 
 
 
INTERMEDIATE SYNDROME: 
Even though the clinical features are first described by Wadia23, he called  it as 
type 2 paralysis. It was Senanayake24 & Karalliedde who introduced the term 
intermediate syndrome in 1987. Exact incidence has not been shown in Indian 
studies.  
Shailesh et al , found the incidence of intermediate syndrome to be 
18%.Incidence varies between 20 – 70 %. 34,35 
Because of the appearance of symptoms between the  early cholinergic phase  
and the late onset peripheral neuropathy it is called as intermediate syndrome. 
Usually develops 12-96 hours after exposure to OP compound. The 
pathophysiology behind the development of intermediate syndrome indicates 
that  there is  a prolonged action of acetylcholine on the nicotinic receptors. It is  
characterized by ocular, neck, bulbar, proximal limb  muscle  weakness  and  it 
also leads to respiratory muscle weakness which ultimately result in respiratory 
failure.  Sometimes  dystonic posturing may be observed  which may be the first 
clue /manifestation of this syndrome. There are no documented sensory 
abnormalities in this syndrome  ,it remains exactly normal. 
Time taken for full recovery despite prompt management will be on  4-18 days. 
 during this stage  there is a Prolonged suppression of the enzyme 
acetylcholinesterase  and metabolites of the parent compound are excreted in 
urine. 
Electrophysiological studies:36 In the first few days of intermediate syndrome, 
shows  either decrements at low frequencies of stimulation (1 to 3 Hz), with 
normal series at 10, 20 or 50 Hz,  with normal findings at both low and 50 Hz 
frequencies were recorded.. All the above said abnormalities suggest that it is  a 
post-synaptic defect. 
 De-Bleecker et al 35 in a review of 19 cases of intermediate syndrome in  
organo-phosphorous poisoning concluded  that in the early stages that CMAP 
showed a decremental response at lower frequencies. This responses were 
maximal at the second response, with gradual  recovery by the ninth response, 
most off the time remain incomplete. Normal  electromyography were recorded 
in the days before  clinical recovery of  this syndrome. According  to him these 
abnormal findings on electromyography suggested a combination of presynaptic 
and postsynaptic defect.  
OPIDN –Organophosphorus induced delayed neuropathy37 
OPIDP - Organophosphorus induced delayed polyneuropathy 
These both terms can be used interchangingly. 
It is one of the delayed neurotoxic complication  of organophosphorus 
compound. 
Usually occurs after 5 weeks of toxin exposure. Exact cause is not known. 
According to  Jokanovic et al., in 2002 states that these effects are not as such 
due to acetyl cholinesterase by itself. 
The same finding was supported by ERDMAN in 2004. 
This  complication  is not only related to exposure of organophosphorus 
compounds but also seen in carbamate exposure. 
HISTORY: 
The ability of these compounds in causing neuropathic complication was 
identified in late 18th century. 
It was Lorot  in 1899 described six cases of multiple neuritis in patients with  
tuberculosis treated with preparations of "phosphocreosote" later found to have 
TOCP. 
Later the same compound was found in adulterants of Jamaican ginger extract 
who suffered from similar illness  in 1930s , about  600 Indians who  consumed 
rapeseed oil contaminated with TOTP  in 1988 reported a similar illness. 
Many  such  incidences has been reported.. 
But not everyone who consumes this compound develop this complication. The 
susceptibility  varies. Numerous animal studies are carried out to demonstrate 
the pathophysiology.  
TOCP /TOTP is present not only in pesticides but also in lubricants ,fuels and 
other plastic industries. 
Some  of the neuropathy inducing OP compounds are 
TOCP                     Tri-ortho-cresyl phosphate 
TOTP                     Tri-ortho-tolyl phosphate 
EPN                      O-ethyl O-p-nitrophenyl phenylphosphonothioate 
DFP                       Di isopropyl phosphorofluoridate 
Leptophos             O-4-bromo-2,5-dichlorophenyl Insecticide 
                               O-methyl phenyl phosphorothioate 
No specific structures or similarities has been found responsible for this 
neuropathic complication except for the pentavalent phosphorus atom which is 
attached to oxygen  by a covalent coordinate bond. 
NEUROPATHOLOGY: 
Primary lesion involves degeneration of distal regions of large, long 
myelinated axons. 
Later it  progresses to Wallerian-like degeneration 38 of affected fiber regions.  
The primary lesion usually reside in a distal non terminal axonal region, then 
extension of these alterations to the terminal axonal endings. 
So the Regions with pathologic involvement include bilateral long peripheral 
nerves and of brain or spinalcord long tracts such as fasciculus gracilis, and 
spinocerebellar, spinolivary, rubrospinal reticulospinal tracts. 
 Usually Neuronal-cell bodies are spared . 
MECHANISM OF TOXICITY39: 
Even though the clinical  manifestation  occurs after a prolonged latent period, 
the first event i.e inhibition of NTE occurs within few hours. 
NTE  -  neuropathy target esterase 
Otherwise called as  neurotoxicesterase. 
It is a carboxyesterase enzyme (with phospholipase activity)  found in both 
neuritic and non neuritic cells of the human body. 
It is encoded in PNPLA6 gene. Though the exact functions has not been 
elucidated it has its role in neural outgrowth and differentiation of neuritic 
tissue.  
For inhibiting this enzyme the OP compound should be in its oxon form. It is 
not enough  to just  inhibit the NTE it should be significant inhibition i.e 70%  
to cause irreversible polyneuropathy. 
 
The exact relationship between NTE and OPIDN has not been defined. Even 
though  NTE is present in in non-neural cells like kidneys, lymphocytes, but no 
adverse effects of OP-induced inhibition of NTE have been noted outside the 
nervous system.  
There is no correlation between the levels of NTE and clinical feature because 
continued NTE inhibition is not necessary for OPIDN. Activity will come back 
to pre-exposure levels before  evidence of the neuropathy develops.  
 Another proposed  mechanism involved in OPIDN is an imbalance in calcium 
homeostasis. It lead to the activation of calcium-activated neutral protease 
thereby  increasing the calcium/calmodulin-dependent protein kinases.  It 
contribute to aberrant phosphorylation of cytoskeletal proteins and protein 
digestion in the terminal axon. This results in  Wallerian type of degeneration. 
Experimental studies are still going on in this aspect whether replacing normal 
homeostasis of calcium can prevent this complication. 
CLINICAL FEATURES: 
Usually begins with sensory symptoms in the form of tingling, numbness in the 
distal extremities. First start with lower limb then progresses to upper limb. 
But sensory neuropathy alone is not the sole manifestation of  OPIDN 
especially in humans. 
Later  slowly the motor symptoms develop in the form of flaccidity of muscles 
in the distal extremities. Weakness usually will be bilateral symmetrical.  This 
results in locomotor defects such as  high stepping gait. Ataxia has also been 
reported.   
 As the disease progresses in severe forms quadriplegia with foot and wrist drop 
are seen, as well as mild pyramidal signs. (Jokanovic, Stukalov et al. 2002) 
Electrophysiological studies of OPDIP organophosphate suggest  features of 
axonal neuropathy, such as slowing of both motor and sensory conduction. it 
also have evidence of chronic denervation of distal muscles.  
 
PROGNOSIS: 
 
Usually the recovery happens only in the sensory symptoms. Motor symptoms 
persist. Sensory symptoms resolve over ensuing 1-2 months. 
 Patients with mild cases recover over several months; those with more serious 
polyneuropathies have persistent effects.  (van Gemert 1999; Kwong 2002)  
Functional recovery  also depends on the degree of pyramidal involvement and  
presence of ataxia(, Stukalov et al. 2002). 
 So far No specific treatment has been identified. ( Dewhurst 2000)  
There are controversies regarding the  early administration of pralidoxime and 
atropine .It has been concluded that it does not seem to prevent the condition. 
(Tareg et al. 2001) 
 
DIAGNOSIS OF ORGANO-PHOSPHORUS POISONING: 
 1.History of exposure to or consumption of organophosphorus   poisoning  
2. Symptoms  like loose stool , dyspnoea and sweating 
3 Signs of poisoning like smell of opc , tachypenea, miosis  fasciculation, neck 
muscle weakness,  
 4. Effect of pralidoxime and atropine  
 5.Inhibition of the cholinesterase activity in the blood 
 
 
 
 
 
CHOLINESTERASE40: 
These are the group of enzymes which metabolize acetylcholine in to acetic 
acid and choline . There are two types of  cholinesterase. One is 
acetylcholinesterase and another is  butyrylcholinesterase. 
 
PROPERTIES ACETYLCHOLINESTERASE BUTYRYLCHOLINESTERASE 
SYNONYM  RBC CHOLINESTERASE PLASMA /PSEUDO 
CHOLINESTERASE 
SITE  NM JUNCTION 
RBC SURFACE 
PLASMA (PRODUCED BY 
LIVER) 
SUBSTRATE  ACETYL CHOLINE BUTYRYL CHOLINE 
EASE OF 
AVAILABILITY 
LITTLE DIFFICULT (NOT 
AVAILABLE IN ALL THE 
CENTRES ) 
 
BETTER   
ACCURACY  GREATER  COMPARATIVELY LESS 
ONSET OF 
DEPRESSION  
LATER  EARLY  
DEPRESSION 
LASTS FOR 
DAYS TO WEEKS EVEN  UP TO MONTHS 
   
 Even though many methods are available for determining cholinesterase 
inhibition, the usual method of analysis is based on the method of Gal and 
Routh (, as performed on the Dupont automated clinical analyzer instrument.  
In this method  butyrylthiocholine is used as a substrate. It  is hydrolyzed by 
the enzyme plasma cholinesterase to  thiocholine. This  thiocholine in turn 
reacts with a colored dye, 2,6-dichlorophenol,later  converted to a colorless 
form.  
The total decrease in absorbance is measured. 
The Dupont instrument tests the level of cholinesterase present in the blood 
serum.  
 The sample should  be taken before the administration of  drugs such as 
Pralidoxime  since it will alter the levels of cholinesterase in the serum. 
 Based on the Marshfield methods of testing, reference values have been for 
the normal population as follows. 
 In  Males: 10.1-22.1 U/ mL (units per milliliter) 
 In  Females:  8.3-20 U/ mL 
Clin. Chem. Acta 1957; 2:316) 
Grading according to cholinesterase activity41: 
20-50% of cholinesterase activity –Mild poisoning. 
10-20% of cholinesterase activity – Moderate poisoning. 
<10% of cholinesterase activity     -  Severe poisoning. 
 
 
 
 
 
 
 
MANAGEMENT OF ACUTE ORGANOPHOSPHORUS POISONING 42 
 OPC poisoning is a medical emergency. They should be admitted in ICU with 
adequate ventilation. The health care workers should wear personnel protecting 
equipments. Rubber Gloves and gowns are recommended.OPC poison penetrate 
latex /vinyl gloves. For respiratory protection charcoal cartridge. masks are 
recommended 
   1. SUPPORTIVE MEASURES:             
     Oral suction of secretions             
      Maintenance of circulation              
      Establishment of respiration   
2. PREVENTION OF ABSORPTION:              
      Decontamination              
      Emesis            
      Adsorbents             
      Cathartics             
      Bowel wash   
3. SPECIFIC THERAPY: 43,44,45         
      Atropine   
      Oximes   
      Treatment of complications  
 
 
SUPPORTIVE MEASURES:  
 Upper airway  should be cleared of secretion by intermittent suction . If airway 
compromise present should be intubated.   Commonest cause of death is 
respiratory failure. If patient develops signs of respiratory failure positive 
pressure ventilation should be given .  
a. Decontamination: 
    Contaminated clothing should be changed, Person should be washed with 
copious   amount of water and soap as opc are hydrolyzed. Skin folds and 
underside of fingernails and long hairs require special attention . Ocular 
decontamination is more important with water or normal saline. Repeat wash 
may be needed in incontinent patients.  
b. Emesis: 
     Emesis should be initiated if the patient is conscious, not  convulsing or has 
intact the gag reflex . If the patient is comatosed, convulsing or has lost the gag 
reflex  gastric lavage should preceded by endotracheal intubation.   
c. Adsorbent: 
If the patient present within 3 hours of ingestion  activated charcoal can be 
given. It may be useful  upto 12 hours after ingestion in case of delayed gastric 
emptying.  
 
d. Cathartics: 
Cathartics  decreasing absorption and increasing elimination of poisoning. 
e. Bowel wash :  It helps to remove the unabsorbed toxic substance from large 
bowel. It is  done twice a day. 
SPECIFIC THERAPY:  
ATROPINE:  
Atropine is physiological antidote for organophosphorus poisoning. It 
effectively antagonise muscarinic post synaptic membrane receptor mediated 
effects (bronchial secretion, salivation, increased sweating, bradycardia etc) and 
in the CNS. 
 
Patient preferably to be oxygenated prior to atropine. 
DOSING OF ATROPINE: 
There are plenty of literature regarding the dosing  schedule of atropine.  
Thirty eight different dose schedule has been described. Final concluding thing 
is  have to give a bolus till the needs achieved. Then continuously have a 
maintenance dose. 46 
The peak effect of atropine is at three minutes. So reassess the patient every min 
till the signs of atropinization is achieved.  
The loading dose atropine  should be 1.8-3 mg  rapidly IV. Further dose should 
be repeated at every 5-10 minute according to muscarinic symptoms like 
bradycardia, miosis, bronchorrea are relieved.  
Other routes of atropine delivery includes nebulisation which also helps in 
improving the oxygenation.  
At emergency situations atropine can also be given via endotracheal tube 
because of its property of  absorbing via mucous membrane.   
The aim of anti cholinergic  treatment is drying of the secretions of 
tracheobronchial tree and other secretions, and increasing the heart rate. Early 
response to atropine is pupillary dilatation.   
Infusion of atropine at a dose of 0.02-0.08mg/kg/h can also be used.  
This  therapeutic  approach has significant reduction in mortality  when 
compared with intermittent therapy. This should be monitored every 15 
minutes. 
If atropinization is lost, again give bolus of atropine and the infusion rate should 
be increased. If there is a evidence of atropine toxicity, atropine infusion should 
be stopped and treat the toxicity. After settle down of signs of toxicity infusion 
can be restrated  at a rate of 70-80% of previous rate. After reduction of rate of  
infusion  patient monitored hourly then 2-3 hourly. Infusion of atropine need to 
be continued for 2-5 days and  tapered  over 3-7 days.  
Atropine should be particularly used in caution in elderly individuals with 
coronary artery disease in whom tachycardia will precipitate failure.  
Tachycardia  itself  is not a contraindication to atropine treatment (A heart 
rate>140 should be avoided). 
TARGET OF ATROPINE THERAPY: 30 
1. Pulse rate should be more than eighty. 
2. SBP maintained more than 90 mm Hg. 
3. Lung should be cleared from secretions; no wheeze/crepts 
4.  Axilla should be dry. 
5. Pupil should not be pinpoint. 
 
PHARMACOLOGY OF ATROPINE: 
NATURAL SOURCE OF ATROPINE: 
It is a plant alkaloid derived from atropa belladona or death shade and in Datura 
stramonium, sacred Datura or datura or thorn apple. 
ABSORPTION: 
Well absorbed from the gut and conjunctival membranes even absorbed across 
the skin. 
DISTRIBUTION:  
Widely distributed in the body.  Atropine also crosses the blood brain barrier 
and counteracts the effects of acetylcholine accumulation in the CNS.   
Significant levels achieved in CSF within 30minutes to 1hour. 
METABOLISM AND EXCRETION: 
Elimination occur in 2 phases namely fast  and slow phase. The t1/2 of rapid 
phase is 2 hours and slow phase is 13 hours. 
About 50% of the drug excreted unchanged in urine. The parasympathetic effect 
last longer in eye for >72hours. 
 
PHARMACODYANAMICS: 
Atropine is reversible blocker of  muscarinic receptor. Binding of atropine to 
muscarinic receptor prevents release of  inositol triphosphate (IP3) and 
inhibition of adenyl cyclase.  Salivary, bronchial and sweat glands are highly 
sensitive to atropine.  Parietal cells of stomach is least sensitive. Atropine is 
highly selective for muscarinic receptor. Atropine has no difference at 
M1,M2,M3 receptors. 
EFFECT  ON VARIOUS ORGAN SYSTEM: 
CENTRAL NERVOUS SYSTEM: 
In usual doses has minimal CNS stimulant effect on medullary parasympathetic 
centre and long lasting sedative effect on brain. 
EYE:   
Mydriasis, Cycloplegia, reduce lacrimal secretion. All these effect contributes to 
the blurred vision following atropinization which may sometimes even last up 
to one week.  
CARDIOVASCULAR SYSTEM:  
 In Low doses it will cause bradycardia by blocking  prejunctional M1 receptor. 
shorten the PR interval on ECG by blocking muscarinic receptor in A-V node. 
Moderate  dose cause tachycardia by blocking vagal slowing. In toxic doses 
cause intraventricular conduction disturbances due to local anesthetic action. 
Atropine block parasympathetic mediated coronary dilation. Blood pressure  
level is minimally affected by atropine.  
RESPIRATORY SYSTEM:   
Atropine cause bronchodilation, reduce the bronchial  secretion.  
GASTROINTESTINAL TRACT:  
Reduces the  salivary secretion more than gastric secretion. G.I smooth muscle 
motility decreased from stomach to colon. Gastric emptying delayed, intestinal 
transit time prolonged. 
 GENITOURINARY TRACT:   
Relaxes the smooth muscle of the ureters and bladder wall and  slow voiding 
.No effect on uterus.  
SWEAT GLANDS:  
Thermoregulatory sweating  is suppressed by atropine. In adults atropine fever 
is common following a  large dose where as in children and infants its common 
even with  small doses.   
 
 
ATROPINE TOXICITY:  
Atropine toxicity manifests as dry mouth, dry flushed hot skin, dilated pupil, 
excitement, delirium, palpitation, hypotension, cardiovascular collapse, 
convulsions and coma.  
Most of these features are indistinguishable from acute organophosphorus 
poisoning. This condition should be identified and adequate  dose adjustment 
should be made.   
GLYCOPYRROLATE: 47 
 Glycopyrolate (0.5mg/kg), a quaternary ammonium compound,  may be 
substituted for atropine, if there is no evidence of central toxicity. It has got 
many theoretical advantages over atropine for treatment of organophosphorus  
poisoning. It does not cross the blood brain barrier thus eliminating the potential 
for  central effects. There is also less tachycardia and better control of bronchial 
secretions  and hence lower incidence of respiratory infections.  
OXIMES- CHOLINESTERASE  REACTIVATORS48,49,50:    
 Pralidoxime (2-Hydroxy iminomethyl- 1 –pyridinium chloride, 2-PAM; 
pyridine 2 aldoxime methyl chloride)  
 Actions of pralidoxime:  
1. Reactivation of cholinesterase by cleavage of phosphorylated active sites  
2. A direct reaction and detoxification of unbounded organophosphorus  
     molecules 
3. Endogenous anticholinergic effect. 
2-PAM binds to the area where the compound has attached to and blocked the 
enzyme cholinesterase. Then the drug attaches to the inhibitor and take it off  
from the enzyme cholinesterase, making the enzyme to function normally. This 
process is referred to as “regeneration” of cholinesterase. 
 Pralidoxime works by competing for the phosphate moiety of the OP 
compound  
and releasing from the acetyl cholinesterase enzyme. 
This action only occurs shortly after poisoning and inhibition of enzyme, after 
which the enzyme “Ages” and becomes irreversibly inactivated.  
 
What is aging ?  
After a period of time this inhibitors forms a strong irreversible bond with the 
enzyme. So oximes cannot bind with the enzyme after this bonding. This 
particular times varies in respect to each compound. Beyond that time oximes 
have no  
beneficial role.  
 Some of the examples given by hoffman include soman in which it occurs in 2 
minutes, VX it takes 40 hours. 
Role in Carbamate poisoning: 
Pralidoxime has actually no role in carbamate toxicity because the bond formed 
between the toxic compound and enzyme lyses on its own within a few hours. 
The bond usually do not undergo the aging process. Usually the symptoms 
recover within a few hours.     
 Although pralidoxime is most effective when administered early, it continues  
to have salutary effects for a prolonged period of time after exposure. The 
oximes are probably most effective if given within 6hours of poisoning. Early 
evidences  
suggested that to be successful, cholinesterase reactivators must be administered 
within 24-48hours of exposure to organophosphates. 
There Are Certain Situations In Which Oximes Have To Be Given For Long 
Time Or It Can Be Started Even After The Period Speculated For Aging. Three 
Such Situations Are Described In Literature. 
1 . Compounds which are soluble in fat will remain there for long time and 
release after  the speculated time which leads to clinical manifestations later due 
to reinhibition of enzymes. 
2. For a op compound to cause clinical features  it should form a  active 
metabolite. it will take some time. 
3 .Some  time skin exposure will cause delayed manifestations. 
  Pralidoxime is renally excreted and within 12hours 80% of the dose has been  
recovered  unchanged in the urine. The plasma half life is 75minutes.  
 The adult dose is 1-2g (of pralidoxime chloride) in 100-150mL of 0.9% sodium 
chloride given intravenously over 30minutes. This dose can be repeated  
in hour if muscle weakness and fasciculations are not relieved. This dose should 
be  
repeated  at every 6-12hours interval for 24-48hours. This may result in 
reappearance of toxicity before the next dose because the serum concentration 
would be expected to fall to less than therapeutic levels within several hours. So 
a continuous infusion of 500mg/hour has been advocated for severe poisoning.  
Maximum dose advised by British national formulary is 12 grams per day.    
ADVERSE EFFECTS: 
 Adverse effects of 2-PAM in humans have been absent or minimal and may  
not be evident until very high plasma levels (400mg/mL).  
1.Transient dizziness, Dry mouth  
2. Visual disturbances (transient) secondary to raised intraocular pressure. 
3. Elevation of diastolic BP may be related to the rate of infusion.  
4. Rapid IV administration even at routine dose of 2gms over 10 min has been 
documented to  produce sudden cardiac arrest. 
5. Higher doses can even itself produces neuromuscular blockade.  
6. Interacts with  atropine and sometimes precipitate  atropine toxic effects.  
 Other oximes: The use of sugar oximes (the molecular combination of glucose  
with 2-PAM derivatives) to promote CNS penetration appears promising. 
OBIDOXIME : 
(Toxogonin) contains two active sites per molecule and is more potent than 2-
PAM. The H series of oximes (named after Hagedorn) HI-6, HJ-6 have been 
developed against chemical warfare nerve gases. In addition to reactivating 
cholinesterase they have direct central and peripheral anticholinergic effects. 
It was Eyer F et al., who studied the effect of Obidoxime in  
organophosphate poisoning in relevance to their clinical features and 
cholinesterase level. The study revealed that this oxime particularly 
responds to parathion rather than other OPCs. 
PHARMACOKINETICS: 
Elimination half life :  6.9 h                             
Vd: 0.845 L/kg 
Renal clearance : 69 mL/min  
Obidoxime dose must be titrated according to renal function. Further 
randomized controlled trials  are must to determine the therapeutic window of 
this compound with organophosphate intoxication. 
 
Jokanović M et al.,51,52conducted a trial of comparison between 3 oximes and 
HI6 in OP compound poisoning in rats. The study provens that even oximes is 
the effective antidote in phosphonate compounds. It concluded that 
Trimedoxime was the most effective drug in treatment of  OP poisoning in rats. 
No such trials are available in humans.   
 
MANAGEMENT OF COMPLICATIONS  OF  ORGANOPHOSPHORUS  
POISONING: 
a.  Seizures:  Benzodiazepine.   
Diazepam IV (Child: 0.2 to 0.5 mg/kg, repeated every 5 minutes as needed 
Adult:     5 to 10 mg,  Q 10 to 15 minutes as needed). 
If seizures recur,  phenobarbital 10 mg (children > 5 years) or 30 mg (adults). 
b.   Hypotension : IVfluids  
 Place in trendelenburg position.   
Infuse 10 to 20 mL/kg isotonic fluid.   
 If  hypotension  persists,  administer norepinephrine (0.1 to 0.2 mcg/kg/min) or 
dopamine  (2.5  to  20  mcg/kg/min)  and  titrate accordingly.    
c.   Pulmonary Edema (Noncardiogenic) :   
Maintain ventilation and oxygenation and evaluate with frequent ABG or  pulse  
oximetry  monitoring.  Early  use  of  PEEP  and  mechanical  ventilation  may  
be  needed.   
d.  Eye Exposure :   
Repeated washing of eyes  with cold water. 
Drugs contraindicated in organophosphorous poisoning :   
1.   Succinylcholine. 
2.   Phenothiazines. 
3.   Antihistamines. 
4.   Opiates. 
5.   Barbiturates. 
6.   Epinephrine. 
7.   Aminophylline. 
                                QTc INTERVAL 
QT interval in ECG indicates the time taken for the ventricle depolarization and 
repolarization. 
It is calculated  from start of Q wave up to end of T wave.  
 
 
Ideally it should be measured in lead 2 or in V5 -6. 
It should be measured in two successive leads. The maximum with in the two 
should be taken. 
There is always a confusion in measuring QT interval. Because of the presence 
of U wave ,which makes to differentiate the end part of T wave. 
To  avoid that slope intercept method is used. 
 
     
 
In  this method the T wave end is defined as the intercept line which is  
tangential line drawn across maximum slope of T wave. 
When there are notches in the T  wave as in the second graph ,,the tangent line 
is drawn from maximum slope down to second part of the notch T2 . 
Whenever the U wave is large and when it is found to be fused it should e 
incccluded in the measurement. large wave is defined as U wave more than 
1mm. 
Some literature mentioned that the tip of the notch should be considered as the 
end of T wave for all practical purposes. 
When U wave is separate or small it can e excluded from the QT interval 
measurement. 
QT interval varies significantly with heart rate. since it is the representation of 
the action potential of the myocardium, which in turn depends on the rate. It is 
the rate which estimates the repolarisation time.  
The QT interval won’t change instantly in response to the rate.  It will take 1 to 
3 minutes for full adaptation. This too varies individually. 
It is not fixed to have same change in QT interval in response to rate. It also 
depends on the associated sympathetic discharge for example the hanges will e 
less during the cold pressor test.   
But it is not the rate alone which determines the QT interval it is influenced by 
numerous other  process which will be discussed below. 
It may be physiological , pathological  or most importantly pharmacological. 
PHYSIOLOGICAL VARIATIONS IN QT INTERVAL: 
The normal variability is accounted to some unknown genetic factors. 
 QT interval increases with age . 
Females normally have increased QT in   comparison with  males. 
QT interval decreases by 20 milliseconds in men after puberty ,but this is not 
found in case of females. 
As with any other metabolic changes in our body QT interval also changes in 
respect to circadian rhythm. The reason is not known for the prolonged  QT 
interval  during the night.  
PATHOLOGICAL VARIATIONS IN QT INTERVAL: 
Congenital long QT interval due to channelopathies (mostly genetic). 
Alcoholic with histological evidence of cirrhosis shows prolonged QT interval 
in most of the studies. 
Prolonged  QT interval will be also seen in anorexia nervosa. 
Exercise  increases the heart rate which in turn influence the QT interval. A 
study has been done  in this influence of rate in exercise to change in QT 
interval.they  concluded that two third of the changes can be attributed to the 
rate ,remaining due to various autonomic changes related to catecholamine 
secretion.  
Corrected QT interval53  : 
Since 1920 there are dozens of formula to correct QT interval. But almost every 
thing involves the correction with respect to rate. All having its own limitations 
. Most commonly  used is Bazzets formula. 
The initial formula formulated by him was QT= k * square root of RR 
  Fridericia proposed a cube-root formula: 
QT= k *cube root of RR 
 Where k value is 0.37 in men and 0.40 in women which was measured to a QT 
interval measured at a heart rate of 60 beats per minute.  
At present, Bazett’s formula is used in the following  form: 
 
 It is expressed in terms of seconds. 
The major limitation of bazett formula  is that  When heart rate is particularly 
fast or slow, this formula may overcorrect or undercorrect, respectively. 
The cube root Fridericia formula has the same limitations as said above but at 
limited to only slow heart rates.This formula is considered as a more accurate 
correction factor in individuals  with tachycardia. 
There is no clear guideline to say what is  the best formula to be utilized in 
clinical practice.54 
 In normal situations  with heart rates of  60-90 beats/min range, almost  all  the 
formulae give similar results for the diagnosis of QT prolongation.  
 
It was  Ashman who first proposed the logarithmic formula which defines 
 
QT  = K1 x log(10 x [RR + K2]) 
where K2 = 0.07; K1 = 0.380 for males & 0.390 for females.   
 
But in  low heart rates, the results given by this formula are too low. 
 
 Adams  proposed  the first linear formula has been  
 
                    for women:  QT = 0.1259 x RR + 0.2789  
     
                    for men:       QT = 0.1536 x RR + 0.2462 
   
Schlamowitz    proposed the  following  formula  for the general population: 
  QT = 0.205 x RR + 0.167   
Even if the rate dependence of the QT interval is probably best described by an 
exponential relation, in the normal heart rate range the QT-RR relation is 
approximately linear. 
In young adults during sleep there will be a increase in heart rate so Bazett , 
Hodges formula tends to overestimate the correction where as Framingham & 
fredrichia underestimate the correction. But its found that  Hodges is better 
during sleep.   
Various formulas has been described    
But nothing has been proved one is superior to other.  
 
B and k: are regression parameters.  
 
Exp: exponential function with base e = 2,718. 
Bazett modified by 
Taran and Szilagyi  
  
QTc = QT / (RR)½ 
Fridericia  QTc = QT / (RR)(0,33) 
 
Framingham  
 
QTc = QT + 0,154 (1−RR) 
Lecocq  QTc = QT/RR(0.314) 
 
Malik  QTc = QT/RR x 0,371 
 
Sagie  QTc = QT + 0.154 (1 – RR)  
 
Boudolas  QTc = QT + 2,0 (FC – 60) 
 
Schlamowitz  QTc = QT + 0,205 (1 – RR) 
 
Wohlfart  QTc = QT + 1,23 (FC – 60) 
 
Larsen and Skulason  QTc = QT + 0,125 (1 – RR) 
 
Mayeda  QTc = QT/RR x 0,604 
 
Kawataki  QTc = QT/RR(0,25) 
 
Van de Water  
 
QTc = QT – 0,087 (RR – 1000)  
 
Matsunaga  QTc = log (600) QT / (log RR) 
 
Sarma 
 
QTc = QT - B1 Exp (-k1 . RR)  
QTc = QT [1-Exp (-k2 . RR)] 
QTc = QT (RR)½ + B3 
QTc = QT (RR)½ * 
 
Hodges  QTc = QT + 1,75 (FC − 60) 
 
Strength equation  QTc = 453,65 × RR1/3.02 (R2 = 0,41) 
 
FC: heart rate.  
RR: RR distance. 
* It is stated that this formula is better than Bazett’s 
 
NORMAL QT INTERVAL: 
  
 
 
 
 
WHY QT INTERVAL IS PROLONGED IN OP POISONING ? 
The exact pathophysiology of cardiac manifestations and electrocardiogram 
changes remains unknown. 
The common ECG manifestations includes sinus bradycardia, sinus tachycardia, 
prolonged PR interval ,prolonged QTc interval ,VPCs,ventricular tachycardia 
,torsades de pointes. 
Prevalence varies in different studies conducted at various places. 
It was ludomirsky et al., 55 who proposed three different phases involved in 
cardiotoxicity of OPC poisoning. 
Phase 1:  
Increased sympathetic activity which is very transient which is followed by  
Phase2: 
Increased parasympathetic activity  
Phase 3: 
QTc slowly starts increasing then when severe may lead to TDP ultimately 
ventricular tachycardia. 
 
This is because of this changing phases some presents with tachycardia some 
with bradycardia. 
Not all patients with prolonged QTc are at risk of having ventricular 
tachycardia(67%)   
This is the ECG of one of our patients who show sinus bradycardia with 
prolonged  
QTc. 
Other examples are attached at the end. 
 
 
  
 
 
 
 
MATERIALS  AND METHODOLOGY 
PLACE OF  STUDY: 
This study was conducted at the Department of  Internal Medicine at Thanjavur 
Medical college hospital during  JANUARY 2014- AUGUST 2014. 
TOTAL NUMBER OF PATIENTS INCLUDED IN THE STUDY : 
70  patients (including both males & females). 
GEOGRAPHIC DISTRIBUTION: 
Patients included in this study were from Urban & Rural areas of Ariyalur, 
Perambalur  , Thanjavur, Thiruvarur and Pudhukottai districts. As already  
discussed in the introduction this is a place where this OP compounds are 
handled in large amounts so it is a suitable place to conduct a study.   
INCLUSION CRITERIA: 
Patient with history of OPC POISON consumption. 
(those who brought the container showing  the chemical name of the compound. 
Oral evidence are not taken in to account)  
 
 
EXCLUSION CRITERIA: 
1.Those not given consent for the study. 
2. Unknown poisoning even with clinical features suggestive of OPC. 
3. Patients treated outside with atropine. 
4. Known coronary artery disease patients. 
5. H/O arrhythmias in the past / those who are on Anti arrhythmic  agent. 
6. Those who taking drugs prolonging QT interval. 
PROCEDURE: 
Patients admitted in casualty with history of OPC consumption satisfying the 
above inclusion and exclusion criteria are selected. 
After obtaining informed consent from the patient’s relative, the patient was 
evaluated in detail based on history of presenting illness. 
Detailed clinical examination done as per the protocol and recorded in the 
proforma.   
The following investigation are done in all patients admitted with OPC 
compound  poisoning. 
1. RBS-Random blood sugar 
2. Sr. UREA /CREATININE 
3. Sr.SODIUM & POTTASIUM 
4. ELECTROCARDIOGRAM 12 LEADS: 
12 LEAD ECG IS TAKEN IMMEDIATELY AFTER ADMISSION 
BEFORE ATROPINISATION. 
THEN THE FOLLOWING PARAMETERS ARE ASSESED IN THE 
ECG. 
1. RATE  
2. RHYTHM 
3. PR INTERVAL 
4. QT INTERVAL 
5. QTc by  BAZZETs FORMULA 
6. ST T CHANGES 
7. ANY VPCs. 
The patient  was followed up till their discharge/death. Their course of stay in 
the hospital was noted. 
Outcome was compared with   QTc interval Statistical analysis was made using  
SPSS software.      
Ethical committee clearance has been obtained for all the above said 
procedures. 
 
 
 RESULTS: 
TABLE 1: SEX DISTRIBUTION 
 
 
 
 
 
 
TOTAL  NUMBER OF PATIENTS INCLUDED IN THE STUDY   WAS 70. 
AMONG THEM NUMBER OF MALES WERE 60 i.e) 85.7 %  
AMONG THEM NUMBER OF FEMALES WERE 10 i.e) 14.3%  
GIVEN BELOW IS THE GRAPHICAL REPRESENTATION OF THE SEX DISTRIBUTION  
GRAPH 1: 
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SEX  DISTRIBUTION  
SEX No.of respondents (n=70) 
Percentage 
(100%) 
Male 60 85.7 
Female 10 14.3 
 TABLE 2: TIME FOR HOSPITALIZATION 
 
  
 
 
 
 
 
THE PATIENTS ARE CLASSIFIED IN TO TWO GROUPS  BASED ON THE TIME OF 
ARRIVAL TO HOSPITAL. 
37%  OF THEM REACHED WITH IN 4 HOURS.  
63%  OF THEM REACHED AFTER  4 HOURS.  
SHOWN BELOW IS THE GRAPHICAL REPRESENTATION OF THE TWO GROUPS. 
 
GRAPH 2: 
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       TIME  TO ARRIVE  No.of respondents (n=70) 
Percentage 
(100%) 
Below 4hrs 26 37.1 
4 to 12hrs 44 62.9 
TABLE 3: SYMPTOM DISTRIBUTION 
THIS TABLE SHOWS THE SYMPTOMATOLOGY OF THE PATIENTS. 
 
SYMPTOMS             NO OF RESPONDENTS 
(n=70)    
                   PERCENTAGE 
ASYMPTOMATIC 7 10.0 
LOOSE STOOLS 48 68.6 
SWEATING 58 82.9 
DYSPNEA 44 62.9 
 
GRAPH 3: 
THIS GRAPH SHOWS THE SYMPTOM DISTRIBUTION OF PATIENTS IN OUR STUDY. 
 
10 % PRESENT WITHOUT ANY SYMPTOMS. 
MOST OF THEM PRESENT WITH SWEATING (82.9%) , FOLLOWED BY LOOSE STOOLS 
(68.6%) , THEN DYSPNEA IN 62.9 % OF INDIVIDUALS. 
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TABLE 4: DISTRIBUTION OF VARIOUS COMPOUNDS TAKEN 
 
 
MOST  COMMON COMPOUND ENCOUNTERED IN OUR STUDY  IS MONCHROTOPHOS 
(31.4%)  FOLLOWED BY CHLORPYRIPHOS (27.2%),   METHYLPARATHION (22.8 %) 
METHYLPARATHION (11.4%)  FINALLY  QUINOPHOS (7.1%). 
GRAPH 4: 
  
 
 
NAME OF THE COMPOUND  
NAME OF THE COMPOUND NO OF PATIENTS TAKEN 
N=70 
PERCENTAGE (100%) 
CHLORPYRIPHOS 19 27.2 
MONCHROTOPHOS 22 31.4 
METHYLPARATHION 16 22.8 
DIMETHOATE 8 11.4 
QUINOPHOS 5 7.1 
TABLE 5: DISTRIBUTION OF PULSE RATE 
 
               ALMOST  57 % PATIENTS PRESENTED WITH NORMAL  PULSE. 
35.7 % PRESENTED WITH BRADYCARDIA. 
ONLY 7.1 % PRESENTED WITH TACHYCARDIA. 
 
GRAPH  5: 
THIS PICTURE IS THE GRAPHICAL REPRESENTATION OF ABOVE CLINICAL 
DATA. 
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PULSE RATE/MIN NO OF RESPONDENTS 
(N=70) 
PERCENTAGE 
<60 25 35.7 % 
60-100 40 57.1 % 
>100 5 7.1 % 
TABLE 6: DISTRIBUTION OF SYSTOLIC BLOOD PRESSURE 
 
 
 
 
 
 
 
 
MOST OF THE PATIENT (58.6 % ) SYSTOLIC BP IS WITH IN THE LEVEL OF 
90 –120 MM HG. 
ONLY 8.6 % PRESENT WITH SBP >120 MM HG. 
GRAPH  6: 
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SYSTOLIC BLOOD 
PRESSURE (MM HG) 
No. of 
respondents 
(n=70) 
Percentage 
(100%) 
Below 90 MM HG 23 32.9 
90 to 120  MM HG 41 58.6 
Above 120 MM HG 6 8.6 
TABLE 7: DISTRIBUTION OF RESPIRATORY RATE 
 
RESPIRATORY 
RATE PER MIN 
NO.OF 
RESPONDENTS 
(N=70) 
PERCENTAGE 
(100%) 
              < 20 46 65% 
>20 24 35% 
 
 
MOST OF  THEM HAD RESPIRATORY RATE LESS THAN 20 (65%). 
35% HAD RESPIRATORY RATE > 20. 
 
GRAPH 7: 
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TABLE 8: DISTRIBUTION OF PUPIL SIZE 
 
 
 
 
 
 
 
 
 
MORE THAN 50% PRESENTED WITH PUPIL SIZE LESS THAN 2 MM. 
47.2 % PRESENTED WITH PUPILS > 2 MM 
NO INEQUALITY WAS NOTED IN THE SHAPE OF THE PUPIL.  
NO ABNORMALITY IN REACTION TO LIGHT. 
GRAPH 8: 
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1 11 15.7 
2 26 37.1 
3 31 44.3 
4 2 2.9 
TABLE 9: DISTRIBUTION OF SERUM SODIUM 
Sodium levels (mEq/L) 
No.of respondents 
(n=70) 
Percentage 
(100%) 
Below 135 mEq /L 13 18.6 
135 to 145 mEq /L 43 61.4 
Above 145 mEq /L 14 20.0 
 
AROUND 61.4% HAD NORMAL SODIUM LEVELS 
ONLY 20% HAD SODIUM LEVELS MORE THAN 145 mEqL 
BELOW IS GRAPHICAL REPRESENTATION OF THE SAME DEPICTED ABOVE. 
 
GRAPH 9 
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TABLE 10: DISTRIBUTION OF SERUM POTTASIUM 
 
POTTASIUM 
LEVEL (mEq/L) 
NO.OF 
RESPONDENTS 
(N=70) 
PERCENTAGE 
(100%) 
BELOW 3.5 mEq/L 10 14.3 
ABOVE 3.5 -5.0 
mEq/L 
60 85.7 
 
60  PATIENTS HAVE NORMAL POTTASIUM VALUE. 
10 PATIENTS  HAVE HYPOKALEMIA. 
GRAPH 10:   
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TABLE  11: NEED OF VENTILATOR 
     
ABOUT   25 %  PATIENT NEEDS VENTILATOR AMONG THE 70 PATIENTS. 
BELOW IS THE GRAPHICAL REPRESENTATION OF THE VENTILATOR NEED IN 
PATIENTS. 
 
GRAPH 11: 
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YES 18 25.7 
NO 52 74.3 
TABLE  12: MORTALITY  RATE  IN OUR STUDY 
 
OUTCOME  
NO.OF 
RESPONDENTS 
(N=70) 
PERCENTAGE 
(100%) 
DEATH 12 17.1 
ALIVE 58 82.9 
 
OUT OF 70 PATIENTS, 12 PATIENTS DIED. 
MORTALITY RATE IN THE STUDY IS  17.1 % 
GRAPH 12: 
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TAbLE 13:DESCRIPTIVE STATISTICS OF THE STUDY POPULATION 
 
 
ITEM  MIN. MAX. MEAN  S.D 
TIME TO ARRIVE 2 12 5.57 2.476 
PR / MIN 44 100 67.07 11.808 
SBP MMHG 68 136 100.74 14.019 
RR / MIN 8 32 13.37 3.253 
PUPIL SIZE (MM) 1 4 2.34 .778 
NA 2+ 128 154 140.14 5.876 
K+ 2.70 5.40 4.0057 .51972 
RATE IN ECG 50 102 69.59 11.876 
THE MAXIMUM AND MINIMUM VALUES IN EACH GROUP ALONG WITH THEIR MEAN AND 
STANDARD DEVIATION IS GIVEN IN THE ABOVE TABLE. 
THESE VALUES WILL BE USED FOR FURTHER ANALYSIS OF THE RESULTS 
 
 
 
 ANALYSIS OF RESULTS: 
TABLE 14: 
THIS TABLE COMPARES THE OUTCOME OF THE PATIENT WIHH 
THAT OF THE SEX OF THE INDIVIDUAL .  
 
 
 
 
 
 
 
BY CHI SQUARE   TEST THERE IS NO ASSOCIATION BETWEEN THE SEX OF 
THE INDIVIDUAL AND OUTCOME. 
SO SEX PLAY NO ROLE IN PREDICTING THE OUTCOME. 
 
BUT THE LIMITATION IN THIS STUDY IS THERE IS A GREAT DISPROPORTION 
IN NUMBER OF MALE AND FEMALE CASES.  
LARGE SCALE STUDIES ARE NEEDED TO CONFIRM THE ABOVE SAID FACT. 
 
 
 
SEX 
OUTCOME 
STATISTICAL INFERENCE DEATH 
(N=12) 
ALIVE 
(N=58) 
TOTAL 
(N=70) 
MALE 10(83.3%) 50(86.2%) 60(85.7%) X2=.067 DF=1 
.796>0.05 
NOT SIGNIFICANT 
FEMALE 2(16.7%) 8(13.8%) 10(14.3%) 
TABLE  15: COMPARISON OF OUTCOME WITH RESPECT TO THE TIME OF ARRIVAL 
TIME TO 
ARRIVE 
OUTCOME 
STATISTICAL INFERENCE DEATH 
(N=12) 
ALIVE 
(N=58) 
TOTAL 
(N=70) 
BELOW 4HRS 2(16.7%) 24(41.4%) 26(37.1%) X
2=2.601 DF=1 
.107>0.05 
        SIGNIFICANT 
4 TO 12HRS 10(83.3%) 34(58.6%) 44(62.9%) 
 
 
 The outcome of patients who have arrived more than 4 hours were compared 
with those who present before 4 hours. There is a change in mortality rate with 
respect to time of arrival to the hospital. 
 
It is proven statistically by chi square test. SO  ACCORDING TO OUR 
STUDY  TIME OF ARRIVAL PLAYS A IMPORTANT ROLE IN 
PREDICTING THE MORTALITY. 
 
  
 
   
 
 
  
MORTALITY  IS VERY HIGH IN PATIENTS ARRIVED AFTER 4 HOURS. 
AMONG THE TOTAL DEATH IT OCCUPIES AROUND 83% , 
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TABLE  16:  COMPARISON  OF  OUTCOME WITH  PULSE RATE 
 
 
 
 
 
 
 
THIS TABLE AND CHARTS DESCRIBES THE DEATH IS  MORE IN THOSE WHO 
 PRESENTS WITH BRADYCARDIA WHEN COMPARED TO OTHER GROUPS. 
PULSE RATE HAS A STATISTICALLY SIGNIFICANT ASSOCCIATION WITH 
MORTALITY.  
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PR / MIN 
OUTCOME 
STATISTICAL INFERENCE DEATH 
(N=12) 
ALIVE 
(N=58) 
TOTAL 
(N=70) 
<60  / MIN 10(83.3%) 15(25.9%) 25(35.7%) X2=14.304 DF=1 
.000<0.05 
SIGNIFICANT 
60 TO 100 / MIN 1(8.3%) 39(67.2%) 40(57.1%) 
>100 / MIN 1(8.3%) 4(6.8%) 5(7.1%) 
TABLE 17: COMPARISION OF OUTCOME WIYH RESPECT TO SYSTOLIC BLOOD PRESSURE 
SBP mm hg 
OUTCOME 
STATISTICAL 
INFERENCE DEATH 
(N=12) 
ALIVE 
(N=58) 
TOTAL 
(N=70) 
BELOW 90 mm Hg 10(83.3%) 13(22.4%) 23(32.9%) 
X2=17.472 DF=2 
.000<0.05 
SIGNIFICANT 
90 TO 120 mm Hg 1(8.3%) 40(69%) 41(58.6%) 
ABOVE 120  mm 
Hg  
1(8.3%) 5(8.6%) 6(8.6%) 
The mortality is more if the initial systolic blood pressure is less than 90 mm Hg  
 that is proven statistically with chi square test. AS FOR ANY ILLNESS SBP LESS THAN 90 
MMM HG PLAYS A MAJOR ROLE IN DETERMINING THE OUTCOME OF THE PATIENT .  
 
 
 
 
 
0 
5 
10 
15 
20 
25 
30 
35 
40 
<90mmhg 90-120 mm hg >120 mm hg 
ALIVE 
DEATH 
COMPARISON OF OUTCOME IN RELATION TO SBP 
TABLE 18: COMPARISON OF OUTCOME IN RESPECT  TO  SODIUM LEVELS 
 
NA 2+ mEq/L 
OUTCOME 
STATISTICAL INFERENCE DEATH 
(N=12) 
ALIVE 
(N=58) 
TOTAL 
(N=70) 
BELOW 135 mEq/L 1(8.3%) 12(20.7%) 13(18.6%) X2=1.332 DF=2 
.514>0.05 
NOT SIGNIFICANT 
135 TO 145 mEq/L 9(75%) 34(58.6%) 43(61.4%) 
ABOVE 145 mEq/L 2(16.7%) 12(20.7%) 14(20%) 
 
THE TABLE COMPARED THE OUTCOME OF THE PATIENTS WITH THEIR SODIUM LEVELS  IN THREE 
CATEGORIES: NORMAL, HYPONATREMIA & HYPERNATREMIA . 
THE TABLE REVEALED THERE IS NO ASSOCIATION BETWEEN THE OUTCOME AND SODIUM LEVELS,  
INSPITE OF HYPONATREMIA BEING A INDEPENDENT PREDICTOR OF MORTALITY IN ICU PATIENTS.   
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TABLE 19 : COMPARISON OF OUTCOME IN RESPECT TO  POTTASIUM LEVELS  
 
 
 
 
 
 
 
 
 
                              
THE GRAPH INDICATES THAT POTTASIUM LEVELS HAVE NOT SIGNIFICANTLY ASSOCIATED THE 
OUTCOME OF THE PATIENTS. 
STATISTICALLY ALSO THESE CHANGES ARE FOUND TO BE SIGNIFICANT.  
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COMPARISON OF OUTCOME IN RESPECT TO  POTTASIUM LEVELS 
 
K+ 
OUTCOME 
STATISTICAL INFERENCE DEATH 
(N=12) 
ALIVE 
(N=58) 
TOTAL 
(N=70) 
BELOW 3.5 2(16.7%) 8(13.8%) 10(14.3%) X2=.067 DF=1 
.796>0.05 
NOT SIGNIFICANT 
ABOVE 3.5 10(83.3%) 50(86.2%) 60(85.7%) 
TABLE 20: 
QTc interval in the group is classified in to three groups: normal <430 msec; intermediate  
431—450 msec ; prolonged  >450. 
The number of patients in each group are given in the table as well as in chart format below. 
 
 GRAPH 18: 
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       QT c INTERVAL IN msec 
 
NO OF PATIENTS 
 
                PERCENTAGE 
<430 msec 21 30% 
431 to 450 msec 6 8% 
Above 450 msec 43 62% 
TABLE 21: 
 
 
 
 
 
 
 
 
 
This   table  shows the number of  males with  prolonged QTc is  33. Among 
that mortality rate is 21 % compared to a rate of 14% in those who having 
<430msec. 
Where there is no such difference noted in the female sex.this is shown in the 
following table. 
TABLE 22: 
 
QTc 
female  
Outcome 
Death 
(n=2) 
Alive 
(n=8) 
Total 
(n=10) 
Above 450 2(100%) 8(100%) 10(100%) 
 
 
QTc interval in millisec  
Outcome 
Alive 
(n=58) 
 
Death 
(n=12) 
Total 
(n=70) 
<430 msec 18 3 21(35%) 
431 to 450msec 6 0 6(10%) 
Above 450msec 26 7 33(55%) 
QT c INTERVAL DISTRIBUTION OF ALIVE & DEATH MALE: 
 
 
Among the 10  death in males ,  7 death i.e) 70%  death have QTc more than 
450 milliseonds.  
In those with QTc  <430  milliseconds the number of death is 3. 
Where there is no such gross variability noted in females. 
 
 
 
 
TABLE 23: 
Overall QTc interval in 
milliseconds 
Outcome 
Statistical 
inference Death 
(n=12) 
Alive 
(n=58) 
Total 
(n=70) 
Below 430 msec 
3 
(25%) 
18(31%) 21(30%) X2=16.577 
Df=2 
.041<0.05 
Significant 
431 to 450 msec 0 6(10.3%) 6(8.6%) 
Above 450 msec 9(75%) 34(58.6%) 43(61.4%) 
 
The total number of patients with normal QTc is 21 which constitutes about 
30% total population , those with borderline QTc is 6 which is about 8.6% of 
study population. Those with  prolonged QTc is 43 which occupies about 61.4% 
of the total study population. 
Among the total death in the study population,75% are in the group with  
prolonged QTc , only 25% in the normal QTc group. 
This difference in mortality rate among this 2 groups are significantly higher as 
evidenced by the chi square test with a Df=2. 
Thus proven statistically significant.  
 
In this graph Y axis shows QTc in milliseconds which is graded in to three 
categories  as normal, intermediate, increased. Then number of patients who are 
alive and death are plotted against it which gives the following bar graph. 
Comparitively death are high in those with prolonged  QTc as evidenced 
statistically also. 
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DISCUSSION 
SEX DISTRIBUTION: 
In our study 85% poisoning cases are males , remaining 15% females with 
suicidal intention (95%) being commoner in both sexes. 
This type of sex distribution is seen in most of the studies. One such study is a 
study conducted a study in a civil hospital by Agarwal56, V Bhatnagar  et al., 
regarding OPC poisoning  in India. 
Their study enrolled 65.3% males and 34.7% females. They also noticed that 
suicidal and intentional poisoning being  common as recorded in 80.2% cases 
followed by occupational (9.1%), accidental (6.6%), homicidal (1.6%) and 
unknown (2.5%). 
TIME LAG FOR ADMISSION: 
In our study the time lag between the poison consumption & time of admission 
plays a major predictor in predicting the mortality. We compared two groups 
those who arrived before 4 hours with those who arrived late. Even the 
mortality was higher in the later group , this was statistically significant. But 
there are many compounding factors like the amount of poison , the nature of 
the consumed compound which might have influenced the outcome.     
Kundu et al., conducted a study  at  Burdwan Medical college Hospital to 
identify the predictors of mortality in OPC poisoning patients and found out that 
increased time interval before hospitalization  were associated with higher 
mortality. 
NATURE OF THE COMPOUND: 
OPC compounds are available in different chemical mixture in plenty of 
pesticides. In our study the most common compound encountered is 
Chlorpyriphos , followed by Monochrotophos then Methyl parathion followed 
by Dimethoate & Quinophos. 
No exact studies in India  have analyzed the mortality from the nature of each 
particular compound. Eastern  studies has shown similar results.58  
In our study apart from other predictors the compound also plays a major role in 
moratlity with Monochrotophos being the most lethal one contributing to 60% 
of the mortality. 
HEART RATE: 
In our study most of the patients presented with normal heart rate (57%), 
followed by bradycardia then tachycardia. But most of the studies conducted in 
North India have documented that sinus tachycardia is the most common 
abnormality encountered even before atropinisation.  They have not correlated 
the pulse rate with the mortality. 
In our study the mortality rate has been compared with those presenting with 
rate less than 60 and those with above rate of 60. 
The mortality rate remained significantly higher in group with bradycardia, 
which has also been proved as statistically significant by chi square test. 
 BLOOD PRESSURE 
Blood pressure variation is also a part of cardiovascular manifestation of OPC 
poisoning.  
Madhur et al., 59reported that  hypotension is more common  than hypertension, 
where as Saadeh AM et al., concluded that hypertension is more common. But 
there is a chance of  getting both in case of OPC poisoning. 
In our study 33 % had SBP below 90 mm Hg &59 % had SBP from 90-120 mm 
Hg .  
SBP < 90 mm hg is a indicator of poor outcome which has been proved 
statistically significant in our study. 
SERUM ELECTROLYTES 
Almost 60 % in our study had normal sodium level. 20% had sodium below 135 
mEq/L and another 20% had above 145 mEq/L. 
Regarding potassium level only 15 % had hypokalemia. Remaining all other 
had normal potassium levels. 
Similar results were obtained in the study done by Ludomirsky et al.,55 
In our study there is no statistical correlation between the electrolyte 
disturbances and mortality or any other complication.     
 
 
 
 
 
ECG CHANGES 
COMPARISON OF QTc INTERVAL WITH OUTCOME IN OUR 
STUDY.  
 
QTc interval varies with respect to sex and other physiological variation as 
described in the review of literature. 
Based on electro cardiology society guidelines QTc interval is classified in to 
normal ,intermediate, increased. 
 
                                         
In our study group there are 70 patients including both males and females. 
There are no much significant difference in  QTc interval in our study with 
respect to the sex of the individual. 
This loss of difference in QT interval may be attributed to wide range in sex 
distribution, 85% males & 15% females. No study has compared the QTc 
interval variation in gender aspect. 
The total mortality rate in our study is 17 % which is comparatively quite low 
compared to western and European studies where the incidence of OP poisoning 
itself is rare when compared to ours. 
In our study 62 % of the study population had prolonged QTc. 8 % had 
borderline QTc . 30 % had normal QTc. 
In our study 43 patients had prolonged QTc out of which 33 are males who 
occupies 55% of the male population. 10 are females. Remaining 22 males had 
normal QT c interval who occupies 35% population. 6 males remain in the 
borderline. 
Among the 10 death in males, 7 had prolonged QTc i.e) 70 % of the death.                
3 had normal QTc. 
Almost all the females had QT c more than 450 milli seconds out of which 2 
died.  
Irrespective of the sex of the individual when compared prolonged QTc with 
outcome there is a statistically significant difference.  
75% of the total death (i.e 9 out of 12) comes under the group with prolonged 
QTc 
25% of death occur in normal QTc group(3 out of 12). 
This has been statistically proven by chi square test.   X2 =16.57; Df =2 
0.041<0.05 Thus statistically significant. 
The following studies are comparable to our results. 
DALVIN CP et al., from SETH GS Medical college analyzed the initial 
electrocardiographic changes of  patient admitted with organophosphorus 
poisoning. According to them abnormal  ST-T changes and fall in voltage are 
the most probable prognostic indicators 
 Even if clinical recovery is found such patient with ST-T changes should be       
monitored continuously till the   changes  recovered Usually most of  the 
changes recover at the time of discharge .with intensive monitoring  the 
mortality rate is reduced from 20% to 4%. 
SHADNIA S et al., 65  studied the prognostic importance of QTc prolongation 
in assessing the severity of lesion. In patients admitted with history of OP 
poisoning in the casualty were taken cholinesterase and QTc interval was 
calculated from the initial ECG before atropinization. 
It has been already proven in lot of studies that cholinesterase was a prognostic 
indicator in OP poisoning. Now the patients with normal enzyme levels and 
decreased enzyme levels are compared with QT interval.  
It  has been concluded that QTc prolongation can also be compared to serum CE 
levels. So it can be used as a alternate indicator to asses the severity of 
poisoning. 
More over the atropine requirement was also increased in the group with 
prolonged QTc. 
S.AGARWAL et al .,56 from BJM  Pune quoted that 38% had ECG 
abnormalities with common being the Sinus tachycardia  changes followed by 
ST-T, then sinus bradycardia. 
Paul UK et al.,60 who done in a cross sectional study  at  MGM  on OPC 
poisoning  patient concluded  that prolonged QTc was the commonest 
electrocardiographic  changes followed  by  sinus tachycardia  followed  by 
sinus bradycardia , tachycardia. ventricular tachycardia  was found in 5.6%.All 
the patient`s electrocardiographic changes returned to normal before discharge. 
KARKIP et al.,61  in Singapore evaluated the cardiac complication of  
organophosphorous  poisoning and found  out that cardiac complication are 
common during the initial course of  poison  intake, but they supported the fact 
that they are secondary to hypoxemia or acidosis and electrolyte abnormalities. 
ANAND et al.,62 from Philadelphia studied cardiac both at the time of 
admission and correlated with the  necrobiopsy  finding .there was found that 
myocardial involvement is a result of direct toxicity. 
SAADEH AM et al .,63 conformed that prolonged QTc was most common 
followed  by ST-T changes then sinus tachycardia followed by sinus 
bradycardia. 
CHUANG FR et al 64., in a study done in their  EMD  dept regarding  QTc 
prolongation in organophosphate poisoning. They compared  two groups one 
with qt prolongation other without  QTc  prolongation. Patients with prolonged 
QTc interval are found to have increased mortality (30% Vs 9%) ,increased rate 
of respiratory failure (80%  Vs 35%). So it is proven that complications of OPP 
are more in the group with prolonged QTc.  
 So it is necessary to take a electrocardiogram  in the casualty before treatment 
to predict the prognosis.They also compared the severity with cholinesterase 
level ,in which they concluded that those who come under severe group also had 
QTc  prolongation. 
JANG SW et al., conducted   a retrospective study on   Electrocardiographic 
findings of organophosphate intoxication in casualty. There are 2 groups. The 
group with prolonged QTc, the mortality incidence of respiratory failure and 
frequency of VPC compared with those patients without QTc prolongation.  The 
overall mortality rate and respiratory failure rate were significantly higher. 
They also found that  apart  from  prolonged  QTc  the increased  frequency of 
VPC itself is a independent predictor of mortality in OPC poisoning. 
 SINGH et al.,66 Conducted a study on  the electrocardiographic  and  clinical 
features  
of  parathion  poisoning in  Punjab. Most of them  had sinus  tachycardia  and 
other had sinus bradycardia, transient premature supraventricular beats , 
premature ventricular contractions , RBBB ,ST depression , suggestive of 
ischemia which reverted to normal with recovery of the patient.  
 CHHABRA et al., 67 In India studied the ECG changes  in  patients of 
malathion poisoning. ECG changes observed in 37 % included intraventricular 
conduction disturbances and ST-T change. 
 LUZHNIKOV et al.,68 from   Moscow reported  severe organophosphates 
Poisoning  with ECG changes.  Patients had various arrhythmias and conduction 
abnormalities, also had prolonged QT interval, correlating with severity of 
intoxication and decrease of cholinesterase activity in serum.  Patient who 
exhibited multifocal VPC  which degenerated rapidly into ventricular 
fibrillation. Some patients had atrioventricular and/ or intraventricular 
conduction disturbances. 
KISS AND FAZEKAS et al.,69 conducted a study on correlation of severity of  
patients with organophosphorus poisoning with  ECG changes within 1-20 days 
of exposure. They included prolongation of QT interval and ST-T changes. 
Most of the patients  had multiple premature ventricular beats, ventricular 
tachycardia, and  ventricular fibrillation. Some patients had Bradycardia, 
idioventricular rhythm. 
LUDOMIRSKY et al,.from Israel had noticed that relatively high occurrence 
of ‘torsade de pointes’ ventricular  tachyarrhythmias  in patients intoxicated  
organophosphate. QT interval prolongation was observed in 14 out of 15 
patients. In 6 of these patients ‘torsade de pointes’ was observed within 4  hours 
, until 5 days following exposure and they also demonstrated the advantage of 
treatment with electrical pacing/ isoproterenol as compared with other medical 
measures. 
CHUANGE  et al.,from Taiwan  conducted a study on ECG changes  
which included  QTc  prolongation  in organophosphorus  poisoning over 12 
years. They  found that   QTc  prolongation in 43.5%   patients ,also had higher  
mortality (19.6%) and higher incidence of respiratory failure. QTc   
prolongation also correlated  with  severity  of poisoning. 
MANOJITH  MUKHERRJEE et al.,70 from West Bengal  conducted a 
retrospective analysis of  patients who were admitted over 8years period with 
diagnosis of organophosphate poisoning .They observed  cardiac arrhythmia in 
52%, prolonged QTc in 46%, ST-T changes in 49%, conduction defects in 5%, 
premature ventricular  contractions in 67%.some patient had ventricular 
tachycardia ,hypotension ,heart failure.  
 LCH Tsoi et al.,  assessed  the ECG features of  OP poisoning. He published the 
case series  and insisted regarding cardiac manifestations of poisoning. Among 
the manifestations hypotension and bradycardia was common. Around 67 % 
had prolonged QT interval ,only 9 % had first degree heart block.  
VIJAYAKUMAR S et al.,71 in his prospective study on OP poisoning ECG 
Findings found that 12 patients had QT >0.43 sec ,  8 patients had ST segment 
elevation and inverted T wave. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CONCLUSION 
 
 OF THE SEVENTY OP POISONING CASES 6O ARE MALES ;10 ARE FEMALE. 
o MALE FEMALE RATIO IS 6:1. THERE IS NO  STATISTICAL      
SIGNIFICANCE  OF  GENDER IN  MORTALITY  PREDICTION. 
 MOST COMMON MODE OF EXPOSURE IS ORAL INTAKE & THE INTENTION   
IS MOSTLY SUICIDAL. 
 
 63% OF THE PATIENTS ARRIVED TO THE HOSPITAL AFTER 4 HOURS. 
THIS TIME OF ARRIVAL HAS SIGNIFICANT ROLE IN PREDICTING THE 
MORTALITY. 
 
 MOST  COMMON COMPOUND CONSUMED  IS MONCHROTOPHOS (31.4%)  
FOLLOWED BY CHLORPYRIPHOS (27.2%), METHYL PARATHION (22.8 %) 
METHYLPARATHION (11.4%)  LEAST COMMON IS  QUINOPHOS (7.1%). 
 
o THIS COMPOUND HAS A SIGNIFICANT  INFLUENCCE IN 
MORTALITY WITH MONOCHROTOPHOS & CHLORPYRIPHOS BEING 
MOST  TOXIC. 
 MOST COMMON PRESENTING SYMPTOM IS SWEATING (82%) FOLLOWED 
BY  LOOSE STOOLS (68%) THEN DYSPNEA IN 62 %. 
 
  MOST OF THE PATIENTS IN THE STUDY HAD NORMAL PULSE RATE. 
ONLY SEVEN PERCENT HAD TACHYCARDIA.BUT THE MORTALITY RATE 
WAS HIGHER IN THOSE WITH BRADYCARDIA. 
 
 SIMILAR TO PULSE RATE ,THOSE WHO PRESENTED WITH SBP <90 MM HG 
HAD A POOR OUTCOME AS PROVEN STATISTICALLY. 
 
 26 % IN OUR STUDY NEED VENTILATORY SUPPORT & IT INDIRECTLY 
INDICATES A POOR OUTCOME . 
 
 EVEN THOUGH MILD ALTERTIONS ARE THERE IN THE ELECTROLYTE 
LEVELS(SODIUM AND POTTASIUM), THERE IS NO STATISTICAL 
CORRELATION  WTH THE MORTALITY. 
 
  62 % OF PATIENTS IN THIS STUDY HAD  QTc MORE THAN 450 MILLI 
SECONDS. NORMAL GENDER VARIATION IS NOT OBSEVED IN OUR 
STUDY.     
 
o GROUP WITH PROLONGED  QTc CONTRIBUTES TO 58.6 % OF THE 
MORTALITY. 
o SO PROLONGED QTc ITSELF IS  IS A SIGNIFICANT PREDICTOR OF 
MORTALITY IN ORGANOPHOSPORUS  POISONING  PATIENTS. 
o SO EARLY DETECTION OF QTc PROLONGATION IN ECG AND INITIATION 
OF EARLY INTENSIVE TREATMENT FOR OPC POISONIG MAY REDUCE THE 
MORTALITY. 
 
 
So the main purpose of the study is to tell that electrocardiogram being 
1. easily available, affordable bed side investigation it gives us valuable 
information in predicting the mortality earlier. Thereby increasing the level of 
care and intensification of treatment. 
2.It is advisable to calculate QT c interval in every patient of OPC poisoning 
instead of relaying on costlier cholinesterase in predicting mortality even it has 
its own advantages. 
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ANNEXURE II 
PROFORMA 
A STUDY ON  PROGNOSTIC  SIGNIFICANCE OF  QTc INTERVAL IN THE 
INITIAL ECG OF OPC POISONING PATIENTS. 
 
NAME:        IP NO: 
AGE:        DOA: 
SEX:        DOD/DEATH: 
OCCUPATION: 
 
CHEMICAL NAME OF THE COMPOUND CONSUMED: 
INTENTION OF POISON CONSUMPTION:  ACCIDENTAL / SUICIDAL  
TIME SINCE CONSUMPTION: 
FIRST AID GIVEN(INCLUDING ATROPINE) OUTSIDE OR NOT: 
 
CLINICAL SYMPTOMS: 
 
 
 
 
 
PAST H/O: 
ANY EVIDENCE OF CORONARY HEART DISEASE   Y/N 
ANY  H/O DRUG INTAKE CAUSING PROLONGED QT INTERVAL   Y / 
      YES     NO 
ASYMPTOMATIC   
LOOSE STOOLS   
SWEATING   
BREATHING 
DIFFICULTY 
  
N 
H/O TYPE 2 DM/ SHT /BA  
EXAMINATION: 
CONSCIOUS / DROWSY /IRRITABLE  / UNCONSCIOUS 
VITAL SIGNS: 
    
PULSE RATE 
(PER MIN) 
<60 60-100 >100 
SBP (MM 
HG) 
<90 90-120 >120 
RR (PER 
MIN) 
<20 >20  
 
SPO2:        % IN RA 
SBC: 
NECK MUSCLE WEAKNESS: PRESENT  / NOT 
MUSCLE  FASICULATION: PRESENT /NOT 
PUPIL SIZE: 
LUNG SIGNS: 
 
LAB INVESTIGATIONS: 
1. RBS 
2. SR.UREA 
3. SR.CREATININE 
4. SR.SODIUM 
5. SR.POTTASIUM  
 
DURATION OF THE HOSPITAL STAY: 
 MECHANICAL VENTILATORY SUPPORT NEEDED OR NOT: 
NUMBER OF DAYS OF MECHANICAL VENTILATION:  
ATROPINISATION NEEDED HOW LONG ? 
 
 
OUTCOME OF THE PATIENT: 
 
ELECTROCARDIOGRAM: 
1. RATE: 
2. RHYTHM: 
3. PR INTERVAL: 
4. QRS DURATION: 
5. QT INTERVAL : 
6. QT c INTERVAL: 
7. ST T CHANGES: 
8.PRESENCE OF VPCs:  
 
FINAL IMPRESSION OF THE ECG: 
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ABBREVATIONS 
ABG          Arterial Blood Gas Analysis 
APD          Action Potential Duration 
ARDS       Acute Respiratory Distress Syndrome 
AV Node   Atrio Ventricular Node 
CNS           Central Nervous System 
Camp          Cyclic Adenyl Mono Phosphate 
DAG           Di Acyl Glycerol 
ECG            Electro Cardio Gram 
ENS             Enteric Nervous System 
HR               Heart Rate 
Ig                 Immunoglobulin 
IV                Intravenous 
K+               Pottasium 
Na2+           Sodium 
NTE            Neuropathy Target Esterase 
OPC            Organo Phosphorus Compound 
OPIDP        Organo Phosphorus Induce Delayed Polyneuropathy 
PEEP           Positive End Expiratory Pressue 
PR                Pulse Rate 
PNS              Peripheral Nervous System 
RBS              Random Blood Sugar 
RR                Respiratory Rate 
SA node       Sino Atrial Node 
SBP              Systolic Blood Pressure 
TDP              Torsades De Pointes 
TEPP             Tetra Ethyl Pyrophosphate 
TOCP           Tri-Ortho-Cresyl Phosphate 
TOTP            Tri-Ortho-Tolyl Phosphate 
TSH              Thyroid Stimulating Hormone 
Vd            Volume Of Distribution 
VPC              Ventricular Premature Complex 
VT                Ventricular Tachycardia 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CONSENT FORM 
 
 
 
I __________________________________________  hereby give consent to 
participate in the study conducted by DR .M.BALAMURUGAN, Post graduate 
in the Department of  General Medicine ,Thanjavur Medical College & 
Hospital, Thanjavur – 613004 and to use my personal clinical data and result of 
investigation for the purpose of analysis and to study the nature of disease. I 
also give consent for further investigations 
 
 
Place : 
Date :       Signature of participant 
 
 
 
 
 
 
 
 
 
INFORMATION SHEET 
 
We are conducting a prospective study on A STUDY ON PROGNOSTIC 
SIGNIFICANCE OF QTc INTERVAL IN THE INITIAL ECG OF OPC 
POISONING PATIENTS. 
in the Department of General Medicine , Thanjavur Medical College & 
Hospital, Thanjavur – 613004. 
• At the time of announcing the results and suggestions, name and identity 
of the patients will be confidential. 
 
• Taking part in this study is voluntary. You are free to decide whether to 
participate in this study or to withdraw at any time; your decision will not 
result in any loss of benefits to which you are otherwise entitled. 
 
• The results of the special study may be intimated to you at the end of the 
study period or during the study if anything is found abnormal which may 
aid in the management or treatment.  
   
Signature of investigator  Signature of participant    
Date 
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